Skip to main content

Table 3 Multivariate analyses of overall mortality and treatment discontinuation. Multivariate analysis by a Cox’s proportional hazard model for hazard ratios of overall mortality and treatment discontinuation in patients received cetuximab as salvage treatment for advanced KRAS wild type (exon 2 non-mutant) CRC

From: Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

 

Overall mortality

 

Treatment discontinuation

 

Variable

Adjusted HR (95 % CI)

P value

Adjusted HR (95 % CI)

P value

RCRC (vs. LCRC)

1.45 (1.18, 1.78)

.0003

1.32 (1.08, 1.61)

.0072

Female (vs. male)

1.04(0.90, 1.21)

.5869

1.01 (0.87, 1.16)

.9413

Age (vs. < 50 y)

 

.2962

 

.0783

50-64

0.86 (0.70, 1.06)

 

0.80 (0.66, 0.98)

 

65+

0.94 (0.76, 1.17)

 

0.82 (0.67, 1.01)

 

Stage IV at diagnosis (vs. I-III)a

1.11 (0.95, 1.28)

.1887

1.08 (0.94, 1.25)

.2916

Histology (vs. others)

 

.1096

 

.1524

Mucinous adenocarcinoma

1.55 (0.91, 2.65)

 

1.69 (0.99, 2.89)

 

Non-mucinous adenocarcinoma

1.04 (0.69, 1.59)

 

1.42 (0.93, 2.18)

 

Grade (vs. I)

 

.0009

 

.0023

 II

1.24 (0.88, 1.76)

 

1.02 (0.74, 1.40)

 

 III

1.82 (1.21, 2.74)

 

1.39 (0.95, 2.05)

 

Undifferentiated or unknown

1.75 (1.15, 2.65)

 

1.50 (1.01, 2.22)

 
  1. Abbreviation: HR hazard ratio, CI confidence interval, RCRC right sided colorectal cancer (cecum to hepatic flexture), LCRC left sided colorectal cancer (splenic flexture to rectum), SD standard deviation
  2. aby American Joint Cancer Committee on Cancer (AJCC) system, 6th edition